Singapore, 29 March 2023 — Aevice Health, a Singapore-based MedTech company that specializes in developing remote respiratory monitoring solutions, today announced that its flagship medical device, the AeviceMD Monitoring System, has received approval from the Health Sciences Authority of Singapore (HSA). The award-winning patient management platform, powered by a smart wearable stethoscope, is the first of its kind to be made available in Singapore.

The AeviceMD Monitoring System’s wearable stethoscope is one of the smallest globally that can detect abnormal breath sounds, such as wheezing, and monitor vital signs including heart rate and respiratory rate. The device, which is approved for use in patients three years and above, has a unique form factor that allows for continuous and comfortable monitoring across a wide spectrum of ages from young children to the elderly, where respiratory diseases are more prevalent.

Approved for use in both clinical and home settings, the AeviceMD Monitoring System is versatile, providing healthcare professionals with the opportunity to be flexible with the deployment of the device. In-hospital monitoring, hospital-at-home monitoring, and remote monitoring to complement telehealth are just some of the potential use cases.

Chronic respiratory disease affects over 545 million people worldwide and is one of the leading causes of mortality. Asthma and COPD (Chronic Obstructive Pulmonary Disease), which are prevalent in Singapore and many other countries, contribute significantly to hospital emergency department (ED) visits and readmissions. Early detection of exacerbations can prevent many of these hospitalizations.

The AeviceMD Monitoring System continuously monitors digital biomarkers of interest, providing healthcare professionals with an overview of the patient’s lung health to track progress over time. Patients, who are at risk of exacerbations, can be identified early to prevent readmissions or ED visits.

Adrian Ang, Chief Executive Officer of Aevice Health, said, “This is a momentous milestone for the company and a timely achievement as our pipeline of partnerships in Singapore grows. We are excited to leverage Singapore’s strategic presence in Asia as a medical hub to bring this novel technology into new markets where there is a high prevalence of respiratory diseases.”

With the approval of the AeviceMD Monitoring System, Aevice Health is well-positioned to expand its reach and provide much-needed respiratory monitoring solutions to patients in Singapore and beyond.

About Aevice Health

Aevice Health is a digital health company dedicated to improving asthma and COPD care through its proprietary, non-invasive remote patient monitoring platform and wearable stethoscope, the AeviceMD. Its cutting-edge technology allows for continuous monitoring and real-time disease deterioration tracking, enabling patients to receive personalized care from the comfort of their homes. With actionable insights and effortless treatment response monitoring, healthcare professionals can make timely adjustments for optimized patient outcomes. Aevice Health is on a mission to improve healthcare accessibility, empower patients, and reduce healthcare costs.

More information about the company can be found at www.aevice.com.